COMPASS Pathways

Verified

★ 4.3 / 5

• 500 reviews

COMPASS Pathways is trailblazing the path for FDA-approved psilocybin therapy. They're advancing a proprietary synthetic psilocybin for treatment-resistant depression, with completed Phase 3 trials and an active rolling submission to bring this innovative treatment to patients.

✓ FDA Breakthrough Therapy ✓ NASDAQ Listed

Visit Website → View 1 Products Find in Headshops

Products

2016

Founded

About COMPASS Pathways

COMPASS Pathways (NASDAQ: CMPS) is the largest psychedelic medicine company in the world, developing COMP360 — a proprietary synthetic psilocybin formulation for treatment-resistant depression. With Phase 3 clinical trials completed and an FDA rolling submission underway as of early 2026, COMPASS represents the most advanced effort to bring psilocybin therapy through the pharmaceutical regulatory pathway. The company has also developed a proprietary therapy protocol and trained hundreds of therapists.

Founded By

George Goldsmith, Ekaterina Malievskaia

Special Features

✓ NASDAQ: CMPS publicly traded
✓ COMP360 psilocybin therapy
✓ Phase 3 clinical trials for depression
✓ FDA Breakthrough Therapy designation
✓ Proprietary therapy protocol

Key Mushrooms Used

🍄 Psilocybin Mushrooms

Recognition & Media

Featured In

The New York Times Bloomberg BioPharma Dive STAT News

Quick Facts

Country: UK (London)
Product Categories: Pharmaceutical , Clinical psilocybin , Therapy
Shipping: Clinical Sites Only

Contact

compasspathways.com